Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

Utah land managers released a new map, outlining nearly 60,000 "high risk" wildland urban interface structures all over the ...

Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...

NAXS AB ( ($SE:NAXS) ) has shared an announcement. NAXS AB has repurchased 6,807 of its own shares on Nasdaq Stockholm between 15 and 19 December ...

AI is now a core part of business strategy, and leaders who understand how to use it can make faster decisions, drive ...

Our review of Bay Area data shows that although San Francisco ranks high for social capital, there are significant variations ...

Days after its recent licensing deal with AI chip firm Groq, Nvidia is reportedly acquiring Israel AI firm AI21 Labs for a ...

As a cybersecurity engineer, she leads efforts to uncover and seal the different ways in which data can fall into the wrong ...

A new AI developed at Duke University can uncover simple, readable rules behind extremely complex systems. It studies how ...

The bureau is accelerating a global biometric screening architecture that is designed to identify and disrupt individuals ...